[ad_1]
Shanghai with Hong Kong, July 4, 2021 /PRNewswire/–Arctic Vision, a ChinaBased on the clinical stage of the ophthalmology company focusing on the development of innovative treatments for pan-eye diseases, today announced a new research collaboration with professors. Christopher Liang, Head of Ophthalmology Department and Clinical Professor Hong Kong university (HKU) Discover and develop new neuroprotective therapies for glaucoma.
Glaucoma is a type of optic neuropathy characterized by the progressive loss of retinal ganglion cells (RGC) and is the leading cause of irreversible blindness worldwide.1 In 2020, there are an estimated 76 million glaucoma patients worldwide, of which as many as 22 million suffer from glaucoma. China Alone. 1,2 Currently, the most common treatment is to reduce intraocular pressure (IOP) to slow down the degeneration of the optic nerve. However, despite the adequate control of intraocular pressure, a large proportion of patients with glaucoma still suffer from progressive visual impairment. Therefore, there is an urgent need for new mechanisms to prevent glaucoma-related blindness.
Since the 2010 World Glaucoma Association Consensus Conference, neuroprotection to prevent or delay neurodegeneration of glaucoma in the form of non-IOP-related interventions has been emphasized as an unmet need in glaucoma management.3 However, to date, no neuroprotective therapy has been approved for the treatment of glaucoma. The groundbreaking collaboration between Arctic Vision and the University of Hong Kong to discover new treatments with new mechanisms of action marks a paradigm shift in global glaucoma treatment research methods.
The project has three main goals:
-Regulating mitochondrial activity as a neuroprotective strategy for glaucoma;
-Develop a microRNA-based gene therapy to protect the optic nerve of glaucoma patients;
-Reprogram cell pathways for neuroprotection and nerve regeneration in RGC.
Arctic Vision will sponsor this…
The full story on Benzinga.com
[ad_2]
Source link
